UK F-Gas Regulation Delays Create Supply and Price Pressure for Cold Chain Operators

The UK government's delay in finalizing revisions to British F-gas regulations has created supply uncertainty and price increases for refrigerants used in pharmaceutical cold chain operations. National Refrigerants, a leading UK gas supplier, has advised pharmaceutical logistics operators to engage proactively with suppliers and monitor availability as market conditions tighten.

Regulatory Background

The UK F-gas regulation (SI 2018/842) controls the use and supply of hydrofluorocarbons (HFCs) and other fluorinated greenhouse gases. Following Brexit, the UK operates its own F-gas regime separate from the EU's Regulation (EU) 517/2014, which has undergone significant revisions including phase-down schedules and quota reductions.

The EU's updated F-gas regulation, which took effect January 1, 2024, introduced accelerated HFC phase-down timelines and tighter quota restrictions. Industry participants expected the UK to align its regulation with the EU framework or introduce equivalent measures. As of May 2025, the UK government has not published a revised F-gas regulation, leaving the 2018 framework in place.

Supply and Price Dynamics

UK refrigerant suppliers report two primary drivers of current market pressure:

Phase-down quota exhaustion: Under the existing UK regulation, the national HFC quota for 2025 is based on 2018 baseline levels minus cumulative phase-down percentages. Suppliers report that quota allocations are being consumed earlier in the year than in prior periods, limiting availability in Q2 and Q3.

EU regulatory divergence: The EU's stricter 2024 quotas have reduced refrigerant supply available for export to the UK. UK-based distributors previously relied on EU suppliers to supplement domestic quota. That cross-border supply has contracted as EU suppliers prioritize domestic compliance.

National Refrigerants has not disclosed specific price increase percentages. Industry sources report increases ranging from 15-35% for common HFC refrigerants (R404A, R410A) compared to 2024 average pricing.

Impact on Pharmaceutical Cold Chain Operations

Pharmaceutical wholesale distributors and 3PLs operating temperature-controlled warehouses and refrigerated transport rely on HFC refrigerants for HVAC systems, cold rooms, and transport refrigeration units. Supply constraints and price increases create three operational risks:

Equipment maintenance delays: Refrigerant scarcity can extend downtime for HVAC and refrigeration system repairs. Cold storage facilities typically maintain emergency refrigerant inventory, but prolonged supply disruptions could delay critical maintenance during summer months when cooling demand peaks.

Budget pressure on smaller operators: Mid-size 3PLs and regional distributors operating on fixed-price logistics contracts may lack contractual mechanisms to pass refrigerant cost increases to pharmaceutical clients. Larger operators with annual purchasing agreements may have hedged some exposure.

Regulatory compliance planning: The UK government has not provided a timeline for revised F-gas regulation. Operators planning capital expenditure on new cold storage facilities or transport fleets face uncertainty about future refrigerant availability and compliance requirements. Some operators are evaluating low-GWP (global warming potential) refrigerants or natural refrigerants (ammonia, CO2) as alternatives, but retrofitting existing infrastructure is capital-intensive.

The delay in regulatory clarity compounds operational planning challenges. Pharmaceutical logistics operators require multi-year visibility for equipment procurement and facility design decisions. The current regulatory gap creates risk that UK requirements could diverge significantly from EU standards, complicating operations for distributors with cross-border supply chains.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 US jurisdictions. While the UK F-gas regulation applies to UK-based operators, 147 entities in the directory operate international cold chain networks that include UK facilities or serve transatlantic pharmaceutical supply chains.

The average compliance score in ColdChainCheck's directory is 51/100, placing most entities in the "Fair" tier. The score reflects verified regulatory data points across six dimensions: state licensure, NABP accreditation, FDA registration, recall history, warning letters, and business information accuracy. Temperature control infrastructure and refrigerant compliance are operational requirements tracked at the facility level by state boards of pharmacy and FDA inspections, but refrigerant-specific compliance signals are not currently isolated in the scoring model.

Of the 1,275 entities tracked, 63 hold NABP accreditation (formerly VAWD). NABP's accreditation standards include facility requirements for temperature-controlled storage but do not specify refrigerant type or environmental compliance with F-gas regulations. Entities operating in multiple jurisdictions—particularly those with EU or UK operations—face layered compliance obligations that extend beyond US drug distribution requirements.

Practical Guidance for QA and Compliance Teams

• Verify cold chain infrastructure for international trading partners: Use the ColdChainCheck directory to identify distributors with known UK or EU operations. Contact entities directly to confirm refrigerant procurement strategies and equipment maintenance plans for 2025-2026.

• Review logistics contracts for cost pass-through clauses: If your specialty pharmacy uses third-party cold storage or refrigerated transport, confirm whether refrigerant cost increases trigger contract adjustments. Entities scored in the "Fair" tier (average score 51) may have less negotiating leverage with suppliers than larger operators.

• Monitor UK regulatory developments: The UK Department for Energy Security and Net Zero (DESNZ) has not published a consultation timeline for revised F-gas regulations. QA managers planning facility audits or vendor qualifications for UK-based partners should request written confirmation of refrigerant availability and pricing stability through Q4 2025.

• Document supplier communications: For audit trail purposes, maintain records of supplier advisories regarding refrigerant supply. If a distributor experiences cold chain equipment downtime due to refrigerant scarcity, this documentation supports deviation investigations and CAPA processes.

ColdChainCheck does not currently track environmental or sustainability compliance signals. Refrigerant management and F-gas compliance fall outside the scope of pharmaceutical distribution licensure tracked in the directory. For guidance on cold chain infrastructure standards, see our 3PL licensing requirements guide covering facility-level compliance obligations.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Pharmaceutical distributors and 3PLs should consult with qualified legal counsel and verify all compliance requirements with the relevant regulatory authorities.